Please enable JavaScript to view the comments powered by Disqus.
Slide Show

1 of 6

5 Pharmaceutical Stocks With Big Moats and Bridges

Getty Images


Pharmaceuticals are a tricky business. Public policy, science, R&D, global growth and regulation all play a role, sometimes outsize, in the success of pharmaceutical stocks.

But some Big Pharma companies and a few other industry firms have managed these and other factors better than others. And along the way, they have built up a considerable “moat” – some sort of considerable competitive advantage – around profitable businesses. Some of these same companies are building bridges to further profitability via deep drug pipelines, innovative new treatments and transformative acquisitions.

Here’s a deeper look into five pharmaceutical stocks that have compelling moats, bridges or both. These advantages make them more likely to provide stable growth over the long term.

SEE ALSO: The Best Health-Care Stocks to Buy for 2019


Data is as of Feb. 27.


View as One Page

Sponsored Financial Content